Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences Authors: Cheng Jiang, Luhan Tang, Mingqian Li, Guoqin Xia Published: 2026 ABSTRACT AbstractBackgroundLumateperone, a novel atypical antipsychotic, has emerged as an illuminating hope for patients with schizophrenia and bipolar disorder. While prior studies have employed spontaneous reporting databases and identified over 100 novel adverse events associated with lumateperone, the differences in these adverse events across subgroups remain unclear.ObjectiveThis study provides a comprehensive evaluation of the adverse event profile of lumateperone using the Food and Drug Administration Adverse Event Reporting System database, focusing on the potential differences in reporting adverse events across subgroups.MethodsBased on the results of clinical characteristics and signal detection, the potential differences in reporting lumateperone-associated adverse events across specific subgroups regarding report year, reporter type, sex, age, outcome, indication, and concomitant drug were analyzed using the reporting odds ratio algorithm and Fisher’s exact test with Bonferroni correction. The observed differences were further validated using sensitivity analyses, stratified analyses, and comparative analyses.ResultsThis study identified 1762 reports and 5074 adverse events associated with lumateperone. Notably, females had a higher frequency of reporting nervous system disorders. Tardive dyskinesia was more frequently resulted in serious consequences. Moreover, bipolar disorder patients more frequently reported nervous system disorders, while schizophrenia patients more frequently reported psychiatric disorders.ConclusionsThis study underscores the need for future confirmatory studies into the potential sex, outcome and indication differences in adverse events associated with lumateperone. The findings should be considered preliminary and require further validation.Keywords: lumateperone, adverse event, nervous system disorder, psychiatric disorders, tardive dyskinesia Introduction Mental disorders are clinical conditions characterized by varying degrees of impairment in cognitive, emotional, volitional, and behavioral aspects of mental functioning. Among these disorders, schizophrenia and bipolar disorder are serious conditions that can significantly impact individuals, families, and society. Schizophrenia affects approximately 1% of the global population and ranks among the top ten causes of disability worldwide.1 Individuals with schizophrenia may experience hallucinations, delusions, disorganized thinking, and a diminished ability to function in daily life.2 Bipolar disorder affects approximately 40 million people globally and imposes a substantial psychosocial, medical, and financial burden.3 The condition is characterized by episodes of hypomania or mania, and depression typically represents the predominant illness phase.3 While the manifestations of schizophrenia and bipolar disorder differ significantly, both are associated with abnormal activity of neurotransmitters such as dopamine and glutamate in the brain.4 The medications for treating mental disorders can be mainly divided into 2 types, including typical antipsychotics and atypical antipsychotics. Typical antipsychotics, represented by chlorpromazine, act almost exclusively on the dopamine system.5 Since mental disorders are complex multi-factor diseases, it seems improbable that all symptoms can be treated with a single-target drug.6 Moreover, typical antipsychotics are effective only against positive symptoms of schizophrenia and have high incidence of extrapyramidal symptoms (EPS).7 Currently, typical antipsychotics are considered the second-line treatments for mental disorders.6 Unlike typical antipsychotics, atypical antipsychotics bind to a range of non-dopaminergic targets, including serotonin, glutamate, histamine, alpha-adrenergic, and muscarinic receptors.8 Atypical antipsychotic drugs, such as quetiapine, aripiprazole, and olanzapine, provide significant advantages over typical antipsychotics, including greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer EPS.9 However, atypical antipsychotic drugs may cause weight gain, glucose dysregulation, and dyslipidemia, which are associated with potential long-term cardiovascular health risks, decreased medication adherence, and may eventually lead to clinical deterioration.9 Till now, the current medications for the treatments of mental disorders still have significant limitations, which has spurred the development of new multi-target antipsychotics. Lumateperone, a novel atypical antipsychotic, received approval from the Food and Drug Administration (FDA) in December 2019 for the treatment of schizophrenia and was subsequently approved in December 2021 for the treatment of depressive episodes associated with bipolar I or bipolar II disorder.10 The efficacy of lumateperone could be mediated through a combination of antagonist activity at serotonin, dopamine, and glutamate neurotransmission.11,12 Clinical trials have proven that lumateperone can significantly reduce the severity of symptoms in patients with schizophrenia or bipolar disorder, particularly benefiting those who have experienced metabolic disorders caused by other antipsychotics.13–15 Consequently, lumateperone has emerged as an illuminating hope for patients with schizophrenia and bipolar disorder. As a new drug, it is critical to continuous monitoring adverse events of lumateperone after its post-marketing. The most common adverse reactions induced by lumateperone were headaches, drowsiness, and dizziness.16 Recently, Zhao et al.17 and Sun et al.18 have conducted post-marketing drug surveillance studies on lumateperone and identified over 100 new adverse events, such as mania, hypomania, urinary retention, serotonin syndrome, burning sensation, tremor, migraine, etc. Whereas prior studies have successfully established the spectrum of lumateperone-associated adverse events, only a limited number of studies have reported subgroup-specific differences. Zhang et al. indicated that females and individuals with bipolar II disorder are independent factors for severe adverse events associated with lumateperone, highlighting the need for cautious use in these high-risk populations.19 Nevertheless, how these adverse events are distributed across other subgroups remains largely unexplored. This study analyzed the potential differences in reporting lumateperone-associated adverse events across specific subgroups using the FDA Adverse Event Reporting System (FAERS) database, regarding report year, reporter type, sex, age, outcome, indication, and concomitant drug. The primary objective of this study was to explore potential differences in adverse events that warrant further investigation. Methods Data source and collection The data for this retrospective pharmacovigilance study of lumateperone were extracted from the FAERS database. The data covered the period from the second quarter of 2020 (the quarter when the first adverse event reports of lumateperone was recorded in the FAERS database) to the fourth quarter of 2023 (the most recent quarter available at the start of this study, posted on January 23, 2024). After removing duplicate cases, adverse event reports of lumateperone were identified by searching for the “LUMATEPERONE” in the “prod_ai” column and the “PS” (primary suspected) in the “role_cod” column.20 Concomitant drugs, which were labeled as “SS” (secondary suspect), “C” (concomitant), or “I” (interacting) in the “role_cod” column, were extracted from the adverse event reports of lumateperone.20 After excluding missing data, the clinical characteristics were investigated based on the lumateperone-associated adverse event reports. The preferred term (PT) was categorized into the corresponding primary system organ class (SOC) levels based on the standardized Medical Dictionary for Regulatory Activities (MedDRA) version 25.1. The additional details regarding data source and collection can be found in previously published articles.21 Statistical analysis Four disproportionality analysis methods, including reporting odds ratio (ROR),22,23 proportional reporting ratio (PRR),24,25 Bayesian confidence propagation neural network (BCPNN),23–25 and multi-item gamma Poisson shrinker (MGPS),23–25 were used for lumateperone adverse event signals detection at the SOC and PT levels. Based on the results of clinical characteristics and signal detection, the potential differences in reporting lumateperone-associated adverse events across specific subgroups were investigated using the ROR algorithm and Fisher’s exact test with Bonferroni correction. Then, the observed differences were further validated using sensitivity analyses, stratified analyses, and comparative analyses. The equations and criteria of the algorithms can be found in Supplementary Tables S1-S4. Python 3 programming language in Jupyter Notebook version 6.4.12 was used for data processing and statistical analysis. The additional details regarding statistical analysis can be found in previously published articles.26–28 Results Clinical characteristics and signals detection The DEMO dataset contained a total of 6 658 462 adverse event reports. After removing duplicate reports, the number of adverse event reports decreased to 5 765 498. Finally, 1762 lumateperone-associated adverse event reports and 5074 adverse events were detected. A flow diagram of data collection and analysis of lumateperone-associated adverse events is shown in Figure 1. Flow diagram of data collection and analysis of lumateperone-associated adverse events. Based on the availability of relevant data fields, the clinical characteristics of adverse event reports related to lumateperone, including the report season, reporter country, reporter type, sex, age, weight, dose, frequency, onset time, outcome, and indication were analyzed, as shown in Figure 2. The top 10 ranked concomitant drugs of lumateperone-associated adverse event reports are shown in Figure 3. The reports mainly came from the United States (n = 1761), with only one report from Poland. Weight data were available for only 299 patients. The most common dose of lumateperone was 42 mg (n = 1070), and concentrated in once daily frequency (n = 1033). After excluding false reports and missing data, only 235 reports recorded the onset time. Since there were insufficient reports or subgroup data on reporter countries, weight, dose, frequency, and onset time, this study did not explore the differences in adverse events across these subgroups. The potential differences in adverse events across reporter year, reporter type, sex, age, outcome, indication, and concomitant drug subgroups were specifically investigated. Clinical characteristics of lumateperone-associated adverse events. (a) Report season. (b) Reporter country. (c) Reporter type. (d) Sex. (e) Age. (f) Weight. (g) Dose. (h) Frequency. (i) Onset time. (j) Outcome. (k) Indication. Abbreviations: HP, health-professional; CN, consumer; MD, physician; PH, pharmacist; QD, quaque die (once daily); QOD, quaque omnis die (every other day); QW, quaque week (once a week). Rectangular tree plot of top 10 ranked concomitant drugs of lumateperone-associated adverse event reports. Lumateperone-associated adverse events involved 26 SOCs. The number and signal strength at the SOC levels are shown in Supplementary Table S5. Based on four disproportionality analysis methods, the significant SOCs were “nervous system disorders” and “psychiatric disorders.” At the PT level, 117 significant adverse event signals were detected. Among these, 15 signals were unrelated to lumateperone, which may be induced by product issues, social circumstances, original diseases, or other factors. After excluding the 15 signals unrelated to lumateperone, 102 significant disproportionality signals were detected at PT level. The number and signal strength of 15 lumateperone-unrelated signals and 102 lumateperone-related signals at the PT levels are shown in Supplementary Tables S6 and S7. To reduce noise from rare adverse events and to make multiplicity correction more clinically meaningful, Fisher’s exact test with Bonferroni correction restricted to adverse events with at least 20 cases in the overall reported number. Of the 102 initially adverse events, 25 met this threshold. The significance level of Bonferroni correction was adjusted to 0.05/25 = 0.002. Potential differences across report year subgroups As shown in Fig. 2a, the number of reports was relatively low from the year 2020 to 2021, showed an upward trend in the year 2022 and decreased thereafter. Figure 4a illustrates the potential differences in reporting lumateperone-associated adverse events across report year subgroups. Based on the ROR algorithm and Fisher’s exact test with Bonferroni correction, the years 2022-2023 showed a higher frequency of reported “nervous system disorders” like “migraine,” (2020-2021 vs 2022-2023: “migraine,” ROR 0.09, 95% CI, 0.01-0.69, P .0018). Volcano plots for potential differences in reporting lumateperone-associated adverse events across subgroups. (a) Difference between years 2020-2021 and 2022-2023. (b) Difference between professional and non-professional reporters. (c) Difference between females and males. (d) Difference between patients with age 18-65 years and > 65 years. (e) Difference between serious adverse event and no-serious adverse event. (f) Difference between patients with indication of bipolar disorder and schizophrenia. (g) Difference between reports with concomitant drugs and reports with lumateperone use alone. The sizes of each point represent the number of reports of each PT induced by lumateperone. In these volcano plots, adverse events with at least 20 cases in the overall reported number are shown. Abbreviations: AE, non-serious adverse event; SAE, serious adverse event. To reduce reporting biases across report year, number and signal strength of lumateperone-related signals at the PT level based on reports in years 2020-2021 and 2022-2023 are presented in Supplementary Tables S8 and S9. The report year-based sensitivity analyses revealed stronger signal of “nervous system disorders” like “migraine” in years 2022-2023 [2020-2021 vs 2022-2023: “migraine,” Not-significant vs 5.49 (3.88-7.78)]. Potential differences across reporter type subgroups Regarding the reporter type, the adverse event reports primarily reported by health-professional (n = 740), consumers (n = 613), and physicians (n = 374), with a small number from pharmacists (n = 21). Figure 4b illustrates the potential differences in reporting lumateperone-associated adverse events across reporter type subgroups. Compared with non-professional (consumers), professionals (including physicians, health-professionals, and pharmacists) showed a significantly higher frequency of reporting “nervous system disorders” like “tardive dyskinesia” and “dizziness” (Professional vs Non-professional: “tardive dyskinesia,” ROR 3.65, 95% CI, 1.93-6.87, P < .001; “dizziness,” ROR 1.69, 95% CI, 1.27-2.23, P < .001). Number and signal strength of lumateperone-related signals at the PT level stratified by professional and non-professional reporters are shown in Supplementary Tables S10 and S11. The reporter type-based stratified analyses analogously revealed strong signals of “nervous system disorders” like “tardive dyskinesia” and “dizziness” by professionals [Professional vs Non-professional: “tardive dyskinesia,” 109.03 (81.81-145.31) vs 35.50 (20.08-62.77); “dizziness,” 9.79 (8.29-11.58) vs 4.41 (3.51-5.52)]. Potential Differences across Sex Subgroups Sex-associated data indicate that the number of reports from females (n = 979) was higher than that of males (n = 576). Figure 4c illustrates the potential differences in reporting lumateperone-associated adverse events across sex subgroups. The results revealed that females had a higher frequency of reporting “nervous system disorders” like “dizziness” (Female vs Male: “dizziness,” ROR 1.86, 95% CI, 1.32-2.62, P < .001), while males had a higher frequency of reporting “psychiatric disorders” like “aggression” (Female vs Male: “aggression,” ROR 0.23, 95% CI, 0.10-1.54, P < .001). Number and signal strength of lumateperone-related signals at the PT level stratified by females and males are shown in Supplementary Tables S12 and S13. The sex-based stratified analyses revealed stronger signals of “nervous system disorders” like “dizziness” for females and stronger signals of “psychiatric disorders” like “aggression” for males [Female vs. Male: “dizziness,” 6.78 (5.76-7.98) vs 4.50 (3.34-6.07); “aggression,” 8.33 (4.16-16.68) vs 13.67 (8.58-21.77)]. Potential differences across age subgroups Regarding age data, majority of the reports were from individuals between 18-65 years old (n = 757), followed by over 65 years (n = 57), with a small number from individuals less than 18 years (n = 6). Figure 4d illustrates the potential differences in reporting lumateperone-associated adverse events across age subgroups. Patients aged 18-65 years showed a significantly higher frequency of reporting “headache” (18-65 years vs >65 years: “headache,” ROR 8.09, 95% CI, 1.12-58.37, P < .001). The differences in lumateperone-related adverse events among minors are subject to further investigation due to limited data on patients under 18 years old. Number and signal strength of lumateperone-related signals at the PT level stratified by patients with 18-65 years and over 65 years are shown in Supplementary Tables S14 and S15. The age-based stratified analyses revealed similar trend [18-65 years vs >65 years: “headache,” 3.01 (2.41-3.76) vs Not-significant]. Potential differences across outcome subgroups Out of the 1762 reports, 660 reports led to 715 serious outcomes, classified into 6 categories, including “hospitalization-initial or prolonged,” “death,” “disability,” “required intervention to prevent permanent impairment/damage,” “life-threatening,” and “other serious.” The most common was “other serious” (n = 468). Figure 4e illustrates the potential differences in reporting lumateperone-associated adverse events across outcome subgroups. Most common adverse events were associated with non-serious outcome, and the cases with serious outcome were more frequently associated with “suicidal ideation” and “tardive dyskinesia” (serious adverse event vs. non-serious adverse event: “suicidal ideation,” ROR 70.41, 95% CI, 9.76-507.97, P < .001; “tardive dyskinesia,” ROR 67.03, 95% CI, 9.28-483.91, P < .001). Number and signal strength of lumateperone-related signals at the PT level based on serious adverse event and non-serious adverse event reports are shown in Supplementary Tables S16 and S17. The outcome-based sensitivity analyses revealed strong signals for “suicidal ideation” and “tardive dyskinesia” in serious adverse event reports [serious adverse event vs non-serious adverse event: “suicidal ideation,” 25.31 (19.73-32.45) vs Not-significant; “tardive dyskinesia,” 153.34 (118.62-198.21) vs Not-significant]. Potential differences across indication subgroups Looking at the indication data, the most common indications were “bipolar disorder” (n = 562) and “schizophrenia” (n = 348), which were consistent with the FDA-approved indications. Figure 4f illustrates the potential differences in reporting lumateperone-associated adverse events across indication subgroups. Bipolar disorder patients more frequently reported “nervous system disorders”, while schizophrenia patients more frequently reported “psychiatric disorders” (Bipolar disorder vs. Schizophrenia: “dizziness,” ROR 2.06, 95% CI, 1.33-3.17, P < .001; “tardive dyskinesia,” ROR 3.91, 95% CI, 1.53-10.01, P .0014; “migraine,” ROR 8.88, 95% CI, 1.18-67.06, P .0019; “aggression,” ROR 0.14, 95% CI, 0.05-0.44, P < .001). Number and signal strength of lumateperone-related signals at the PT level, based on reports with “bipolar disorder” and “schizophrenia” indications are presented in Supplementary Tables S18 and S19. The indication-based sensitivity analyses revealed stronger signals of “dizziness,” “tardive dyskinesia” and “migraine” for patients with bipolar disorder and stronger signals of “aggression” for patients with psychiatric disorders [Bipolar disorder vs. Schizophrenia: “dizziness,” 8.56 (6.98-10.49) vs 4.16 (2.84-6.10); “tardive dyskinesia,” 118.39 (84.55-165.78) vs 29.98 (12.44-72.24); “migraine,” 5.53 (3.32-9.19) vs Not-significant; “aggression,” Not-significant vs 31.86 (19.12-53.08)]. Potential differences across concomitant drug subgroups Among the 1762 lumateperone-associated adverse event reports, 792 reports (45%) used concomitant drugs. As shown in Figure 3, lamotrigine (n = 98), lithium (n = 68), and quetiapine (n = 60) were the most common concomitant drugs associated with lumateperone. The top 10 ranked concomitant drugs of lumateperone-associated adverse event reports with bipolar disorder and schizophrenia as indication are shown in Supplementary Figures S1 and S2. The most common concomitant drugs associated with bipolar disorder patients were lamotrigine, lithium, and clonazepam, while the most common concomitant drugs associated with schizophrenia patients were olanzapine, quetiapine, and aripiprazole. The analyses revealed that the adverse events, including “migraine,” “tardive dyskinesia,” “dizziness,” “aggression,” “headache,” “suicidal ideation,” and “nausea,” may have potential differences across subgroups. Figure 4g illustrates the potential differences in reporting lumateperone-associated adverse events between reports with concomitant drugs and reports with lumateperone use alone. Cases with lumateperone use alone exhibited a higher frequency of reporting the common adverse events like “nausea,” “headache” and “dizziness” (Concomitant drugs vs Use alone: “nausea,” ROR 0.38, 95% CI, 0.28-0.53, P < .001; “headache,” ROR 0.52, 95% CI, 0.37-0.73, P <.001; “dizziness,” ROR 0.60, 95% CI, 0.46-0.79, P < .001). To reduce biases induced by concomitant drugs, concomitant drug-based sensitivity analyses were conducted. Number and signal strength of lumateperone-related signals at the PT level, based on reports with concomitant drugs and reports with lumateperone use alone, are presented in Supplementary Tables S20 and S21. All the 7 adverse events were significant based on reports with lumateperone use alone. Comparative analyses Since there are major bias of indication regarding lumateperone and all other drugs, this study performed comparator-restricted disproportionality analysis. Number and signal strength of lumateperone-related signals at the PT level using reports with “bipolar disorder” and “schizophrenia” indication as comparators are presented in Supplementary Tables S22 and S23. When compared against reports with both bipolar disorder and schizophrenia indications, “suicidal ideation” became not significant. Additionally, the comparative analyses still revealed stronger signals of “dizziness,” “tardive dyskinesia” and “migraine” for patients with bipolar disorder, and stronger signals of “aggression” for patients with psychiatric disorders [Bipolar disorder vs. Schizophrenia: “migraine,” 8.69 (4.89-15.44) vs Not-significant; “tardive dyskinesia,” 4.81 (3.36-6.90) vs. Not-significant; “dizziness,” 9.16 (7.28-11.52) vs 5.24 (3.54-7.76); “aggression,” Not-significant vs 5.05 (3.00-8.51)], further proved the potential differences across indication subgroups. Discussion Although prior studies have employed spontaneous reporting databases and identified over 100 new adverse events associated with lumateperone, the potential differences in these adverse events across subgroups remain unclear. In this study, the most common adverse events reported for lumateperone primarily included dizziness, nausea, headache, and somnolence, which align with the prescribing information for lumateperone.29 The new adverse events, including mania, hypomania, urinary retention, serotonin syndrome, burning sensation, tremor, and migraine, which have been identified by the recent post-marketing drug surveillance studies,17–19 were also detected in this study. These results have proved the reliability of the findings in this study. Based on the results of clinical characteristics and signal detection, this study analyzed the potential differences in reporting lumateperone-associated adverse events across specific subgroups using the ROR algorithm and Fisher’s exact test with Bonferroni correction. Currently, the integrated use of ROR algorithm and Fisher’s exact test is widely accepted in the literature for comparing 2 groups.30–34 The ROR provides a direct and easily interpretable effect size estimate. Fisher’s exact test calculates an exact P-value based on the hypergeometric distribution, making it statistically robust and reliable when counts are low. Bonferroni correction was applied for adjustments in multiple comparisons.35 This combination allows to assess both the magnitude (ROR value via ROR algorithm) and the statistical significance (P-value via Fisher’s exact test with Bonferroni correction) of the potential difference between subgroups. Due to the inherent limitations of the FAERS database, the observed differences in reporting lumateperone-associated adverse events may be influenced by several confounding factors, such as stimulated reporting, missing data, indication, and polypharmacy. To further verify the potential differences, this study conducted additional sensitivity analyses, stratified analyses, and comparative analyses. For instance, this study performed a sensitivity analysis by recalculating signals after excluding the reports with concomitant medications. All the adverse events, which have potential differences across subgroups, were significant based on reports with lumateperone use alone, which, to some extent, mitigate the confounding effects of polypharmacy. However, when compared against reports with bipolar disorder or schizophrenia indication, “suicidal ideation” became not significant, indicating that lumateperone did not carry a higher risk of suicidal ideation comparing with other drugs for treating bipolar disorder or schizophrenia. It is hypothesized that suicidal ideation may also be triggered by the underlying disease itself, decline in efficacy, accompanying depression,36,37 and the use of combined medications (such as quetiapine, clonazepam, amphetamine, divalproex, alprazolam, and trazodone).38–41 Therefore, the results regarding suicidal ideation still require further experimental verification and, thus, were excluded from the final research conclusion. To enhance the clinical relevance of the results, this study subsequently analyzed and discussed the primary adverse events with potential subgroup differences through comprehensive literature review and clinical expertise. This integrative approach aims to highlight potential areas of concern that warrant further investigation. It is crucial to emphasize that the observed differences may still stem from confounding factors. As such, the findings should be considered preliminary and require further validation. Potential sex differences This study found a higher number of adverse event reports from females compared to males. This aligns with existing evidence showing that females, particularly those of childbearing age, have a higher incidence of mental disorders.42 The ROR algorithm and Fisher’s exact test with Bonferroni correction revealed that females had a higher frequency of reporting nervous system disorders, which emerged as one of the most significant SOCs. Notably, sex-specific differences may also reflect differential reporting behavior. Therefore, this study conducted further sex-based stratified analyses. The results still revealed stronger signals of nervous system disorders for females, which partially eliminated the influence of the reporting behavior. The nervous system disorders associated with lumateperone may arise from its intrinsic pharmacological properties, which can perturb neurotransmitter balance.9 Studies on risperidone, another antipsychotic, demonstrate a higher incidence of nervous system disorders in females than in males.43 Another study also revealed sex-difference following psychotropic drug administration: extrapyramidal and anticholinergic reactions were more often by females.44 Although the precise mechanisms underlying the sex-related differences of antipsychotic medications are not fully elucidated, two plausible explanatory factors may offer references. Firstly, on average, females achieve therapeutic responses to antipsychotic medications at lower doses than males, particularly with olanzapine and clozapine.45,46 This suggests that many female patients may be receiving inappropriately high doses, thereby increasing their risk of adverse reactions.45 Secondly, studies have confirmed sex-based differences in the expression of hepatic enzymes involved in antipsychotic metabolism, which may partly account for the observed clinical variations in tolerability between sexes.45 Consequently, Seeman suggested prescribing antipsychotics is a science and art, which needs to take sex into account.46 Barbui et al. further advocated that future studies should not treat males and females as a homogeneous group, given the substantial inter-sex differences in the subjective tolerability of antipsychotic drugs.44 These findings suggest a need for further verification of the sex-specific differences in the adverse event profile of lumateperone. Potential outcome differences Regarding the outcome, this study indicated that the cases with serious adverse event were more frequently associated with “tardive dyskinesia.” Tardive dyskinesia is a syndrome characterized by a constellation of iatrogenic movement disorders, which is typically induced by long-term use of dopamine receptor-blocking agents.47 These movement abnormalities include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other involuntary motor symptoms.48 Compared with the first-generation antipsychotics, the second-generation antipsychotics generally target more specific dopamine, and are associated with a lower incidence of tardive dyskinesia.49 A post-marketing safety study for lumateperone raised concerns, as it demonstrated a strong signal for tardive dyskinesia.19 In this study, professionals showed a significantly higher frequency of reporting tardive dyskinesia. Given these findings, vigilant monitoring and strengthening education on consumers are recommended to prevent serious outcomes induced by tardive dyskinesia in patients requiring long-term lumateperone therapy. Once diagnosed, dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered as the preferred treatment option.50 Potential indication differences Lumateperone is primarily indicated for the treatment of schizophrenia and bipolar disorder, which have distinct characteristics. However, no studies have systematically investigated the potential differences in adverse events between these patient populations. Interestingly, our findings reveal a noteworthy potential divergence in the spectrum of lumateperone-associated adverse events between patients with schizophrenia and those with bipolar disorder. Specifically, patients with bipolar disorder exhibited a higher frequency of reporting nervous system disorders, such as dizziness, tardive dyskinesia, and migraine, whereas those with schizophrenia had a higher frequency of reporting psychiatric disorders like aggression. The comparator-restricted disproportionality analysis further proved these potential differences. According to the clinical trials experience, the incidence of dizziness was 11% in a 6-week adjunctive therapy bipolar depression trial, 8% in pooled 6-week monotherapy bipolar depression trials, but 5% in 4-to 6-week schizophrenia trials,29 which indirectly supports the findings that bipolar depression patients may be more susceptible to experiencing dizziness. This, to some extent, was conformity with the potential difference across report year. Before being approved for the treatment of bipolar disorder in 2021, lumateperone was only approved for treating schizophrenia. As the number of bipolar disorder patients using lumateperone has increased after 2021, nervous system disorders have occurred more frequently. The findings underscore the potential influence of underlying disease on adverse event profiles of lumateperone, which warrant further investigation. The precise mechanism of the indication heterogeneity in adverse events has not been reported in the literature yet, but the possible mechanism might be some connection with mechanism of action, pathophysiological features and concomitant medications. Lumateperone has high binding affinity for serotonin 5-HT2A receptors. It also has moderate binding affinity for dopamine D2 receptors, serotonin transporters, dopamine D1 and D4, and adrenergic alpha1A and alpha1B receptors, but has low binding affinity for muscarinic and histaminergic receptors.29 In patients with different underlying conditions, there may be variations in receptor expression and mechanisms of action, which may suggest a potential contribute to the differences in adverse reactions.10 For schizophrenia patients, when the control of positive symptoms is insufficient, the hallucinations and delusions may not be completely suppressed. As a result, it is hypothesized that the resulting fear, misunderstanding, and confusion can manifest as aggressive mental behavioral symptoms. Additionally, for patients with bipolar disorder, they are frequently co-prescribed other serotonergic agents (eg, antidepressants like SSRIs/SNRIs), which may play a potential role for elevating the risk for nervous system disorders. Notably, FAERS database cannot entirely distinguish disease effects from treatment context, illness phase, or polypharmacy patterns. The mechanistic interpretations remain largely speculative and should be framed as hypotheses rather than explanatory conclusions. Further mechanistic studies is needed to explore whether biological pathways of lumateperone action differ across disease contexts. Strengths and limitations This study offers a comprehensive characterization of the potential differences in reporting lumateperone-associated adverse events across various subgroups, revealing several critical safety findings. Firstly, females had a higher frequency of reporting nervous system disorders. Secondly, tardive dyskinesia was more frequently resulted in serious consequences. Thirdly, bipolar disorder patients more frequently reported nervous system disorders, while schizophrenia patients more frequently reported psychiatric disorders. The findings can serve as a starting point for designing prospective studies to formally test these preliminary hypotheses. This study has several limitations. Firstly, majority of the reports included in this study originated from the United States, thus reflecting the circumstances of American patients and not encompassing the adverse events of lumateperone in other countries. Secondly, there were missing data within the FAERS database, potentially introducing bias. Thirdly, the spontaneous nature of reporting introduces the possibility of reporting bias. Fourthly, the results from FAERS database may be confounded by the concomitant medications. For instance, the concurrent use of traditional Chinese medicines, which involved in the regulation of neurological and mental disorders,51–55 could influence the adverse events associated with lumateperone. However, the FAERS lacks detailed information regarding traditional Chinese medicines. Fifthly, this study involved multiple comparisons with Bonferroni correction. Although Bonferroni correction can reduce the risk of false positives, it can also obscure clinically meaningful but weaker signals.56 Sixthly, this study examined adverse event data of lumateperone based on a single database. Although we have searched other databases, such as Japanese Adverse Drug Event Report (JADER) database, no adverse event reports for lumateperone were identified. Consequently, the findings still require further validation from additional external databases. Despite these limitations, this study offers valuable insights into the potential differences in adverse events that warrant further investigation. Conclusions This study underscores the need for future confirmatory studies into the potential sex, outcome, and indication differences in adverse events associated with lumateperone. The findings should be considered preliminary and require further validation. Supplementary Material Acknowledgments We would like to thank the participants and researchers of the FAERS database. Contributor Information Cheng Jiang, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China; Zhejiang Provincial Key Laboratory of Disease-Syndrome Integrated Cancer Prevention and Treatment, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310012, China; Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Pharmacodynamic Material Basis Research of Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. Luhan Tang, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. Mingqian Li, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. Guoqin Xia, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China. Author contributions Cheng Jiang (Data curation [lead], Formal analysis [lead], Writing—original draft [lead]), Luhan Tang (Writing—original draft [supporting]), Mingqian Li (Conceptualization [equal], Writing—review & editing [equal]), and Guoqin Xia (Conceptualization [equal], Writing—review & editing [equal]). All authors have read and agreed to the published version of the manuscript. Conflicts of interest The authors declare no conflict of interest. Funding This study was supported by the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province (2023ZL349), Zhejiang Clinovation Pride (CXTD202-501010), Zhejiang Provincial Department of Science and Technology Research Institute Support Program (KJTYSZX2025), Public Service Technology Research Project of Zhejiang Province (LQ20C090001), and State Administration of Traditional Chinese Medicine Science and Technology Department-Zhejiang Provincial Administration of Traditional Chinese Medicine Co-construction of Key Laboratory of Research on Prevention and Treatment for Depression Syndrome (GZY-ZJ-SY-2402). Data availability Raw data for this article can be downloaded at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html; further inquiries can be directed to the corresponding author. Ethics approval and consent to participate Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database. Author statement All authors confirm that this manuscript is our original work and has not been published nor has it been submitted simultaneously elsewhere. All authors have checked the manuscript and have agreed to the submission. References Associated Data Supplementary Materials Data Availability Statement Raw data for this article can be downloaded at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html; further inquiries can be directed to the corresponding author.